SKB BIO's stock price surged 5.16% at the open on Friday, driven by multiple positive clinical development and regulatory updates from the biopharmaceutical company.

The company announced that its Phase III OptiTROP-Lung05 trial met its primary endpoint, showing that sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab significantly extended progression-free survival compared to pembrolizumab alone in previously untreated patients with PD-L1-positive advanced non-small cell lung cancer. The objective response rate was 70.2% for the combination versus 42.0% for monotherapy, with a favorable trend in overall survival.

Further supporting the move, SKB BIO disclosed that the New Drug Application for its next-generation RET inhibitor, lunbotinib fumarate, has been accepted for review by China's National Medical Products Administration. The company also highlighted that it will present these and other robust clinical data, including positive Phase III results for sac-TMT in triple-negative breast cancer, at the upcoming American Society of Clinical Oncology Annual Meeting, underscoring its advancing oncology pipeline.